The phosphoinositide 3-kinase pathway and therapy resistance in cancer.

Download
Author
Brown, KK; Toker, ADate
2015Source Title
F1000prime reportsPublisher
Faculty Opinions LtdUniversity of Melbourne Author/s
Brown, KristinAffiliation
Biochemistry and Molecular BiologyMetadata
Show full item recordDocument Type
Journal ArticleCitations
Brown, K. K. & Toker, A. (2015). The phosphoinositide 3-kinase pathway and therapy resistance in cancer.. F1000Prime Rep, 7, pp.13-. https://doi.org/10.12703/P7-13.Access Status
Open AccessDOI
10.12703/P7-13Open Access at PMC
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335789Abstract
The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References